drugset

drugset / Trial / NCT02586337

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

NCT02586337 ↗

Phase 2/3 Unknown 113 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Differentiated Thyroid Cancer.

Timeline

Start: 2015-07
Primary completion: 2019-12
Completion: 2019-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	—	Oral

Indications